Report of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors of Dr. Reddy's Laboratories Limited Results of Review of Interim Financial Statements We have reviewed the accompanying c

National Stock Exchange of India Ltd.

New York Stock Exchange Inc.

Sub: Form 6-K for the quarter ended September

30, 2021, filed with United States Securities and Exchange Commission.

This is to inform you that the Company has

filed its unaudited condensed consolidated interim financial statements prepared under IFRS in Form 6-K for the quarter ended September

30, 2021, with the United States Securities and Exchange Commission on November 5, 2021. A copy of the Form 6- K is attached. The

Form 6-K is also available on the Company's website, www.drreddys.com.

This is for your information.

For Dr. Reddy's Laboratories Limited

AND EXCHANGE COMMISSION

Washington, D.C. 20549

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT

TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Quarter Ended September 30, 2021

Commission File Number 1-15182

REDDY'S LABORATORIES LIMITED

(Translation of registrant's name into

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file

annual reports under cover of Form 20-F or Form 40-F.

Indicate by check mark if the registrant is submitting the Form

6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______

Note: Regulation S-T Rule 101(b)(1) only permits the submission

in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form

6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Note: Regulation S-T Rule 101(b)(7)

only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign

private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled

or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which

the registrant's securities are traded, as long as the report or other document is not a press release, is not required to

be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been

the subject of a Form 6-K submission or other Commission filing on EDGAR.

Quarter Ended September 30, 2021

Currency of Presentation and Certain Defined Terms

In this Quarterly Report,

references to "$" or "dollars" or "U.S.$" or "U.S. dollars" are to the legal currency

of the United States, references to "Rs." or "rupees" or "Indian rupees" or "INR"

are to the legal currency of India, references to "MXN" are to the legal currency of Mexico, references to "ZAR"

are to the legal currency of South Africa, references to "UAH" are to the legal currency of Ukraine, references to

"GBP" are to the legal currency of United Kingdom and references to "EUR" or "euros" are to

the legal currency of the European Union. Our unaudited condensed consolidated interim financial statements are presented in Indian

rupees and are prepared in accordance with International Accounting Standard 34, "Interim Financial Reporting" ("IAS

34"). Convenience translation into U.S. dollars with respect to our unaudited condensed consolidated interim financial statements

is also presented. References to a particular "fiscal" year are to our fiscal year ended March 31 of such year. References

to "ADSs" are to our American Depositary Shares. All references to "IAS" are to the International Accounting

Standards, to "IASB" are to the International Accounting Standards Board, to "IFRS" are to International

Financial Reporting Standards as issued by the IASB, to "SIC" are to the Standing Interpretations Committee and to

"IFRIC" are to the International Financial Reporting Interpretations Committee. References to "FVTOCI" are

to fair value through other comprehensive income and to "FVTPL" are to fair value through profit and loss.

FDA" are to the United States Food and Drug Administration, to "ANDS" are to Abbreviated New Drug Submissions,

to "NDAs" are to New Drug Applications, and to "ANDAs" are to Abbreviated New Drug Applications.

References to "U.S."

or "United States" are to the United States of America, its territories and its possessions. References to "India"

are to the Republic of India. References to "EU" are to the European Union. References to "CIS" are to

the Commonwealth of Independent States, which is comprised of certain countries of the former Soviet Union. All references to "we",

"us", "our", "DRL", "Dr. Reddy's" or the "Company" shall mean

Dr. Reddy's Laboratories Limited and its subsidiaries. "Dr. Reddy's" is a registered trademark of Dr. Reddy's

Laboratories Limited in India. Other trademarks or trade names used in this Quarterly Report are trademarks registered in the name

of Dr. Reddy's Laboratories Limited or are pending before the respective trademark registries, unless otherwise specified.

Market share data is based on information provided by IQVIA Holdings Inc. (formerly Quintiles IMS Holding Inc.) ("IQVIA"),

a provider of market research to the pharmaceutical industry, unless otherwise stated.

Except as otherwise stated

in this report, all convenience translations from Indian rupees to U.S. dollars are at the certified foreign exchange rate of U.S.$1.00

= Rs.74.16, as published by Federal Reserve Board of Governors on September 30, 2021. No representation is made that

the Indian rupee amounts have been, could have been or could be converted into U.S. dollars at such a rate or any other rate. Any

discrepancies in any table between totals and sums of the amounts listed are due to rounding.

Our main corporate website

address is https://www.drreddys.com. Information contained in our website, www.drreddys.com, is not part of this Quarterly

Report and no portion of such information is incorporated herein.

Forward-Looking Statements and Risk Factor

In addition to historical

information, this quarterly report contains certain forward-looking statements within the meaning of Section 27A of the Securities

Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In

addition to statements which are forward-looking by reason of context, the words "may", "will", "should",

"expects", "plans", "intends", "anticipates", "believes", "estimates",

"predicts", "potential", or "continue" and similar expressions identify forward-looking statements.

The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results

to differ materially from those reflected in the forward-looking statements. Factors that might cause such a difference include,

but are not limited to, risks relating to:

Readers are cautioned

not to place undue reliance on these forward-looking statements, which reflect management's analysis and assumptions only

as of the date hereof. In addition, readers should carefully review the other information in this quarterly report, in our most

recent Annual Report on Form 20-F for the year ended March 31, 2021 and in our periodic reports and other documents filed with

and/or furnished to the SEC from time to time.

ITEM 1. FINANCIAL STATEMENTS

DR. REDDY'S LABORATORIES LIMITED

UNAUDITED CONDENSED CONSOLIDATED

INTERIM STATEMENTS OF FINANCIAL POSITION

(in millions, except share and per share

The accompanying notes

form an integral part of these unaudited condensed consolidated interim financial statements.

DR. REDDY'S LABORATORIES